Overview
Diagnostic Pathways for Alzheimer’s Disease: Optimizing Multidisciplinary Practices
Simulated Case Challenge to Improve AD Diagnosis
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
A simulated case-based challenge activity that mirrors real-world practice for both PCPs and neurologists to support optimal recognition, diagnostic, and communication practices by clinicians to improve care for patients with Alzheimer disease (AD).
This activity is intended for neurologists, primary care physicians, internists, geriatricians, and NPs and PAs who care for patients with or at risk for AD.
AD is associated with a significant burden for patients, their caregivers, and society. However, detection of AD remains suboptimal with many patients not diagnosed, misdiagnosed, or experiencing a delay in diagnosis. There appears to be a lack of appreciation of the benefits of an earlier, or “timely” diagnosis, for patients and caregivers, which can permit earlier intervention to prolong independence and functioning and improve quality of life. Contributing to this lack of diagnostic expertise, particularly in primary care settings, is a lack of knowledge about appropriate testing methodologies and their interpretation. Finally, the emotional toll of an AD diagnosis can be significant for patients and caregivers, leading many healthcare professionals to delay or poorly communicate the diagnosis. Consequently, this activity has been designed to meet the significant educational needs in identification of symptoms and differential diagnosis; the importance of early diagnosis; use and interpretation of cognitive, imaging, and biomarker assessments; and optimal communication strategies.
Upon completion of this activity, participants will be able to:
- Identify the symptoms of Alzheimer disease to differentiate it from other neurodegenerative disorders and normal aging to gain confidence in making a diagnosis
- Employ and interpret appropriate cognitive, biomarker, and imaging tests in clinical practice to improve diagnosis of Alzheimer disease
- Describe the benefits of earlier diagnosis of Alzheimer disease for patients and caregivers
Supported by an educational grant from Biogen.
Andrew E. Budson, MD
Chief, Cognitive & Behavioral Neurology and Associate Chief of Staff for Education
VA Boston Healthcare System
Associate Director & Education Core Leader
Boston University Alzheimer's Disease Center
Professor of Neurology
Boston University School of Medicine
Lecturer in Neurology
Harvard Medical School
Boston, MA
Chief, Cognitive & Behavioral Neurology and Associate Chief of Staff for Education
VA Boston Healthcare System
Associate Director & Education Core Leader
Boston University Alzheimer's Disease Center
Professor of Neurology
Boston University School of Medicine
Lecturer in Neurology
Harvard Medical School
Boston, MA
Penn State College of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Andrew E. Budson, MD
Author Royalties: Elsevier, Oxford University Press
Grant recipient: Cyclerion, Bristol Myers Squibb
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Penn State College of Medicine staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Questions regarding accreditation can be directed to ContinuingEd@pennstatehealth.psu.edu or 717-531-6483. Refer to course number G6819-22-T.
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
